Synageva BioPharma Completes Target Enrollment in Phase 3 ARISE Trial

Synageva BioPharma GEVA today announced that it met the enrollment target of 50 patients in ARISE (Acid Lipase Replacement Investigating Safety and Efficacy), a global Phase 3 trial with sebelipase alfa in children and adults with lysosomal acid lipase deficiency (LAL Deficiency). To accommodate individuals still in the screening process, total enrollment will exceed the planned number of 50 patients, with the final patient expected to be randomized by the end of this year. As a result of today's enrollment update, the company expects to report top-line results from the ARISE trial during the second half of 2014. See full press release